1620-00-4

Basic information

• Product Name: 1H-inden-3-ylacetic acid
• Synonyms: 1H-Inden-3-ylacetic acid; 1H-indene-3-acetic acid
• CAS NO: 1620-00-4
• Molecular Formula: C₁₁H₁₀O₂
• Molecular Weight: 174.1959
• Mol File: 1620-00-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 345°C at 760 mmHg
• Flash Point: 242°C
• Density: 1.226g/cm³
• Vapor Pressure: 2.41E-05mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: 1H-inden-3-ylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-inden-3-ylacetic acid(1620-00-4)
• EPA Substance Registry System: 1H-inden-3-ylacetic acid(1620-00-4)

Safety Data

• Hazardous Substances Data: 1620-00-4(Hazardous Substances Data)

Usage

Classification

Phytohormone
Found in plants and plays a critical role in growth and development

Function

Natural auxin
Regulates cell division and elongation, root and shoot formation

Physiological processes influenced

Nutrient uptake, fruit development, stress response

Agricultural applications

Promoting root growth in cuttings, enhancing fruit production

Importance

Significant implications for plant biology and agriculture

Upstream product

• 480-90-0 1H-inden-1-one 
• 105-36-2 ethyl bromoacetate 
• 83-33-0 inden-1-one 
• 5796-52-1 inden-1-yliden-acetic acid 
• 4709-56-2 ethyl 2-(1H-inden-3-yl)acetate 
• 1620-02-6 1-Ethoxycarbonylmethyl-1-hydroxy-indan 
• 28002-99-5 1-(ethoxycarbonyl)methyleneindane 

Downstream Products

• 7235-16-7 2,3,4,9-tetrahydro-1H-fluoren-1-one 
• 38425-66-0 2-(indan-1-yl)ethanol 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy

Peroxisome proliferator-activated receptor gamma (PPARγ) is a valuable drug target for diabetic treatment and ligands of PPARγ have shown potent anti-diabetic efficacy. However, to overcome the severe side effects of current PPARγ-targeted drugs, novel PPARγ ligands need to be developed. Sulindac, an identified ligand of PPARγ, is widely used in clinic as a non-steroidal anti-inflammatory drug. To explore its potential application for diabetes, we designed and synthesized a series of sulindac derivatives to investigate their structure-activity relationship as PPARγ ligand and potential anti-diabetic effect. We found that meta-substitution in sulindac's benzylidene moiety was beneficial to PPARγ binding and transactivation. Z rather than E configuration of the benzylidene double bond endowed derivatives with the selectivity of PPARγ activation. The indene fluorine is essential for binding and regulating PPARγ. Compared with rosiglitazone, compound 6b with benzyloxyl meta-substitution and Z benzylidene double bond weakly induced adipogenesis and PPARγ-targeted gene expression. However, 6b potently improved glucose tolerance in a diabetic mice model. Unlike rosiglitazone, 6b was devoid of apparent toxicity to osteoblastic formation. Thus, we provided some useful guidelines for PPARγ-based optimization of sulindac and an anti-diabetic lead compound with less side effects.

-

-

Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions

Substituted methoxy benzylidene indenyl compounds are useful in the treatment of precancerous lesions and neoplasms.